iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype.
about
Circulating glioma biomarkersProteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysisIdentification of novel tumor-associated cell surface sialoglycoproteins in human glioblastoma tumors using quantitative proteomicsIdentification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cellsGene set based integrated data analysis reveals phenotypic differences in a brain cancer model.Systematic mapping and functional analysis of a family of human epididymal secretory sperm-located proteins.CYB5R3: a key player in aerobic metabolism and aging?Stable-isotope dilution LC–MS for quantitative biomarker analysis.Mapping of the human testicular proteome and its relationship with that of the epididymis and spermatozoa.Thyroid hormone enhanced human hepatoma cell motility involves brain-specific serine protease 4 activation via ERK signalingProtein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.PeptideManager: a peptide selection tool for targeted proteomic studies involving mixed samples from different species.LC-MS/MS analysis of differentially expressed glioblastoma membrane proteome reveals altered calcium signaling and other protein groups of regulatory functions.Plasma membrane proteomics and its application in clinical cancer biomarker discovery.Isobaric labeling and data normalization without requiring protein quantitationAnti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastomaAn informatics-assisted label-free approach for personalized tissue membrane proteomics: case study on colorectal cancer.Network signatures of survival in glioblastoma multiforme.Investigation of Pokemon-regulated proteins in hepatocellular carcinoma using mass spectrometry-based multiplex quantitative proteomics.Proteomics of gliomas: initial biomarker discovery and evolution of technology.Proteomics in neurodegenerative diseases: Methods for obtaining a closer look at the neuronal proteome.Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomicsTargeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM).The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status.Pharmacological evidence: a new therapeutic approach to the treatment of chronic heart failure through SUR2B/Kir6.1 channel in endothelial cells.Application of proteomics in the study of rodent models of cancer.Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells.Targeting Malignant Brain Tumors with Antibodies.Changes in the biological characteristics of glioma cancer stem cells after serial in vivo subtransplantation.Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation.
P2860
Q26830329-407E6F17-9E76-43C0-BB80-51B7951DE571Q28484143-000895AB-6173-46BF-9DEB-3427E251CC8AQ28544645-39B37B2F-309C-4EF0-9223-DA0CB433359FQ28710385-23B45F64-7B0C-470D-8CF2-EB72DC711994Q30656585-37C94397-4804-45A0-8DEA-2661BBEBB01DQ33671722-DD4E5349-DB1B-42DC-8E05-39434A93BE10Q33722186-327C0896-A8F4-4F77-8DB9-203FD77AD674Q33747062-DAC41EF8-B1A0-40A7-9759-3D589FFD0BEEQ33778019-AB4F8C5B-D6F7-4312-8A2C-5C7E7B27B48DQ33865519-3E2AD7F2-B8A4-4F04-90DA-E8A4AF9D3ECAQ34042498-ACDD277A-2960-47B6-B129-82BD49C685F5Q34117442-9728D740-2D0A-4DD6-A37E-5631A95A2D20Q34118902-8F944D6D-14C9-4D58-AB57-B5F1C6E3CE82Q34122107-1881EA0C-1472-4D95-B2F5-096C8C5BF347Q34216692-99BDAB38-E9D1-4067-85DE-A19DCE85ADA1Q34621127-BEA5FD07-00A9-49F6-B745-88C9D9527E6FQ34751614-E543E7E4-62E6-4FC8-998B-66425F8FF2B2Q34998178-1ED4A216-62B5-476E-B6D4-77681306FD55Q35049696-27759AE1-B7A9-4FB5-986A-D197D36F75E0Q35170365-7182DD7E-D683-4CC9-A6F9-10AFADBE2557Q35241298-0E9D9565-22B0-4355-AF89-4E82B2A235D0Q36104523-7431E68D-09D4-4375-A895-2CA6E168B8DCQ36539474-94CBE9A2-E502-46FA-96ED-749945F8C8BEQ37109236-9BF1F6A4-C114-4DFD-8FEA-65DF9DA8FD86Q37571935-6B73DB1B-3089-400C-8DCF-77D33FD526A0Q38194543-10C3DEC8-3804-4024-A1AE-D3777AA0250AQ38954199-43CA7E46-DE68-4DCD-95C2-BA574C0DBF92Q42267793-67547DE7-E0A7-4FDE-B856-0D07205CF3A3Q44748938-B02DF1F8-2D60-4F39-8AD1-865FF37D5503Q52862875-D6505DB0-596B-4B26-9389-41F9AF464DCD
P2860
iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
iTRAQ-based proteomics profili ...... vasive glioblastoma phenotype.
@ast
iTRAQ-based proteomics profili ...... vasive glioblastoma phenotype.
@en
type
label
iTRAQ-based proteomics profili ...... vasive glioblastoma phenotype.
@ast
iTRAQ-based proteomics profili ...... vasive glioblastoma phenotype.
@en
prefLabel
iTRAQ-based proteomics profili ...... vasive glioblastoma phenotype.
@ast
iTRAQ-based proteomics profili ...... vasive glioblastoma phenotype.
@en
P2093
P2860
P1476
iTRAQ-based proteomics profili ...... vasive glioblastoma phenotype.
@en
P2093
Connie R Jimenez
Hrvoje Miletic
Jaco C Knol
Kjell Petersen
Maarten Loos
Oleg Klychnikov
Sébastien Bougnaud
Thang V Pham
P2860
P304
P356
10.1074/MCP.M900124-MCP200
P577
2009-08-12T00:00:00Z